Fibrinolytic activity is similar in physically active men with and without a history of myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 6, 1997, Pages 1106-1113

  Fernhall, Bo ^a,c   Szymanski, Linda M ^a   Gorman, Patrick A ^b   Milani, James ^a   Paup, Donald C ^a   Kessler, Craig M ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Coronary artery disease; Plasminogen activator inhibitor; Tissue type plasminogen activator

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPRANOLOL; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EXERCISE; FIBRINOLYSIS; FITNESS; HEART REHABILITATION; HUMAN; MALE; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; THROMBOGENESIS;

EID: 0030919884     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.6.1106     Document Type: Article

References (47)

1. Hamsten A, DeFaire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;July 4:3-9.
2. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation. 1993;88:2030-2034.
3. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993; 342:1076-1079.
4. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis: the ARIC Study. Circulation. 1995;91:284-290.
5. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980 ;303:897-902.
6. Hamsten A, Wiman B, DeFaire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313: 1557-1563.
7. Rydzewski A, Sakata K, Kobayashi A, et al. Changes in plasminogen activator inhibitor-1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease. Haemostasis. 1990; 20:305-312.
8. Kruithof EKO, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost. 1988;59:7-12.
9. Speiser W, Speiser P, Minar E, Korninger C, Niessner H, Huber K, Schernthaner G, Ehringer H, Lechner K. Activation of coagulation and fibrinolysis in patients with arteriosclerosis: relation to localization of vessel disease and risk factors. Thromb Res. 1990;59: 77-88.
10. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
11. Francis RB, Kawanishi D, Baruchi T, Mahner P.'Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J. 1988:115:776-780.
12. Wiman B, Hamsten A. Correlations between fibrinolytic function and short-term, intense myocardial infarction. Am J Cardiol. 1990; 66:54G-56G.
13. Blair.SN, Kohl HW, Paffenbarger RS, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. JAMA. 1989;262: 2395-2401.
14. Powell KE, Thompson PD, Casperson CJ, Kendrick JS. Physical activity and the incidence of coronary heart disease. Annu Rev Public Health. 1987;8:253-287.
15. Stratton JR, Chandler WL, Cerqueira MD, Schwartz RS, Cerqueira MD, Levy WC, Kahn SE, Larson VG, Cain KC, Beard JC, Abrass IB. Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. Circulation. 1991;83: 1692-1697.
16. Szymanski LM, Pate RR, Durstine JL. Effects of maximal exercise and venous occlusion on fibrinolytic activity in physically active and inactive men. J Appl Physiol. 1994;77:2305-2310.
17. Drygas WK. Changes in blood platelet function, coagulation, and fibrinolytic activity in response to moderate, exhaustive, and prolonged exercise. Int J Sports Afed. 1988;9:67-72.
18. Ferguson EW, Bernier LL, Banta GR, Yu-Yahiro J, Schoomaker EB. Effects of exercise and conditioning on clotting and fibrinolytic activity in men. J Appl Physiol. 1987;62:1416-1421.
19. Szymanski LM, Pate RR. Fibrinolytic responses to moderate intensity exercise: comparison of physically active and inactive men. Arterioscler Thromb. 1994;14:1746-1750.
20. Speiser W, Langer W, Pschaick A, Selmayr E, Ibe B, Nowacki PE, Muller-Bergbaus G. Increased blood fibrinolytic activity after physical exercise: comparative study in individuals with different sporting activities and in patients after myocardial infarction taking part in a rehabilitation sports program. Thromb Res. 1988;51:543-555.
21. Aznar J, Estelles A, Tormo G, Sapena P, Tormo V, Blanch S, España F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J. 1988; 59:535-541.
22. Estelles A, Tormo G, Aznar J, España F, Tormo V. Reduced fibrinolytic activity in coronary heart disease in basal conditions and after exercise. Thromb Res. 1985:40:373-383.
23. Hamouratidis ND, Pertsinidis TE, Bacharoudis GP, Papazachariou GS. Effects of exercise on plasma fibrinolytic activity in patients with ischaemic heart disease. Im J Cardiol. 1988;19:39-45.
24. Molz AB, Heyduck B, Lill H, Spanuth E, Rocker L. The effect of different exercise intensities on the fibrinolytic system. Eur J Appl Physiol. 1993;67:298-304.
25. Szymanski LM, Pate RR. Effects of exercise intensity, duration and time of day on fibrinolytic activity in physically active men. Med Sci Sports Exerc. 1994;29:1102-1108.
26. Dill D, Costill D. Calculation of percentage changes in volumes of blood, plasma and red cells in dehydration. J Appl Physiol. 1974;37: 247-248.
27. Chandler WL, Schmer G, Stratton JR. Optimum conditions for the stabilization and measurement of tissue plasminogen activator activity in human plasma. J Lab Clin Aled. 1989; 113:362-371.
28. Drabkin OL, Austin JH. Spectrophotometric studies, II: preparation from washed cells-nitric oxide, hemoglobin, and sulfhemoglobin. J Biol Chem. 1935; 112:51-55.
29. Chandler WL, Trimble SL, Loo S-C, Mornin D. Effect of PAI-1 levels on the molar concentration of active tissue plasminogen activator (TPA) and TPA/PAI-1 complex in plasma. Blood. 1990;76:930-937.
30. Hamsten A. Hemostatic function and coronary artery disease. N Engl J Med. 1995:332:677-678. Letter.
31. Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Aled. 1989:113:88-93.
32. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M, for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemie events in atherosclerotic patients: a case-control study. Arterioscler Thromb. 1993;13:1412-1417.
33. Thompson SG, Keinast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332: 635-641.
34. Epstein SE, Rosing DR, Brakman P, Redwood DR, Astrup T. Impaired fibrinolytic response to exercise in patients with type IV hyperlipoproteinemia. Lancet. 1979;2:631-634.
35. Walker ID, Davidson JF, Button I. "Fibrinolytic potential:" the response to a 5 minute venous occlusion test. Thromb Res. 1976;8: 629-638.
36. Szymanski LM, Durstine JL, Davis PG, Dowda M, Pate RR. Factors affecting fibrinolytic potential: cardiovascular fitness, body composition, and lipoprotein(a). Metabolism. 1996;45:I427-1433.
37. DeGaetano G, Carriero MR, Cerletti C, Mussoni L. Low dose aspirin does not prevent fibrinolytic response to venous occlusion. Biochem Pharmacol. 1986;35:3147-3150.
38. Hammouda MW, Moroz LA. Aspirin and venous occlusion: effects on blood fibrinolytic activity and tissue-type plasminogen activator levels. Thromb Res. 1986;42:73-82.
39. Keber I, Jereb M, Keber D. Aspirin decreases fibrinolytic potential during venous occlusion, but not during acute physical activity. Thromb Res. 1987;46:205-212.
40. Winther K, Gleerup G, Hedner T. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and β-adrenergic receptor blockers. J Cardiovasc Pltarmacol. 1991; 18(suppl 9):S41-S44.
41. El-Sayed MS. Extrinsic plasminogen activator response to exercise after a single dose of propranolol. Med Sci Sports Exerc. 1992;24: 327-332.
42. Andreotti F, Kluft C, Davies GJ, Huisman LGM, de Bart ACW, Maseri A. Effect of propranolol (long-acting) on the circadian fluctuation of tissue-plasminogen activator and plasminogen activator inhibitor-l.Am J Cardiol. 1991;68:1295-1299.
43. Cohen R, Epstein SE, Cohen LS, Dennis LH. Alterations of fibrinolysis and blood coagulation induced by exercise, and the role of betaadrenergic-receptor stimulation. Lancet. 1968:2:1264-1266.
44. Wright RA, Perrie AM, Stenhouse F, Alberti KGMM, Riemersma RA, MacGregor IR, Boon NA. The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease. Eur J Clin Pharmacol. 1994;46:279-282.
45. Sundell IB, Nilsson TK, Hallmans G, Hellsten G, Dahlén GH. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein(a), and established cardiovascular risk factors in a North Swedish population. Atherosclerosis. 1989;80:9-16.
46. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Allan C. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab. 1987;13:331-336.
47. Folsom AR, Qamhieh H, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb. 1993;13:162-169.